Literature DB >> 20522014

Transgenic mouse models of tauopathy in drug discovery.

W Noble1, D P Hanger, J-M Gallo.   

Abstract

Tauopathies, including Alzheimer's disease, are neurodegenerative diseases characterized by the deposition of hyperphosphorylated tau protein in the central nervous system, and are the major cause of dementia in later life. Considerable advances have been made in developing mouse models that recapitulate, to varying extents, the development of human tau pathology, and the learning and memory deficits characteristic of some tauopathies. Furthermore, such models have been used to show promising disease-modifying effects in pre-clinical testing of new therapeutics. Various strategies have been utilised to generate mouse models of tauopathies. Some of the most enlightening models developed to date either constitutively or inducibly express pathogenic tau mutations. These animals have been instrumental in defining critical disease-related mechanisms, including the observation that tangles are not the toxic form of tau in disease. Here, we discuss the strengths and weaknesses of well characterised transgenic models that emulate human tauopathy, and include a comprehensive listing of the main phenotypic characteristics of all reported tau transgenic rodents. We summarise the use of tau mice for the development and evaluation of new therapeutic approaches, and their utility in identifying novel drug targets. In addition, we review the parameters to be considered in the development of the next generation of mouse models of tauopathy, aimed at further increasing our understanding of disease aetiology and in evaluating novel treatments.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20522014     DOI: 10.2174/187152710791556131

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  20 in total

Review 1.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Ectopic Expression Induces Abnormal Somatodendritic Distribution of Tau in the Mouse Brain.

Authors:  Atsuko Kubo; Shouyou Ueda; Ayaka Yamane; Satoko Wada-Kakuda; Mai Narita; Makoto Matsuyama; Akane Nomori; Akihiko Takashima; Taisuke Kato; Osamu Onodera; Motohito Goto; Mamoru Ito; Takami Tomiyama; Hiroshi Mori; Shigeo Murayama; Yasuo Ihara; Hiroaki Misonou; Tomohiro Miyasaka
Journal:  J Neurosci       Date:  2019-06-24       Impact factor: 6.167

Review 3.  Therapeutic Strategies for Restoring Tau Homeostasis.

Authors:  Zapporah T Young; Sue Ann Mok; Jason E Gestwicki
Journal:  Cold Spring Harb Perspect Med       Date:  2018-01-02       Impact factor: 6.915

4.  Live-Cell Imaging Reveals Tau Isoforms Imbalance Disrupts Traffic of APP Vesicles in Human Neurons.

Authors:  Christy Oi Ying Hung
Journal:  J Neurosci       Date:  2017-02-22       Impact factor: 6.167

5.  Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity.

Authors:  Allyson V McCormick; Jeanna M Wheeler; Chris R Guthrie; Nicole F Liachko; Brian C Kraemer
Journal:  Biol Psychiatry       Date:  2012-11-07       Impact factor: 13.382

6.  Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice.

Authors:  Magali Dumont; Cliona Stack; Ceyhan Elipenahli; Shari Jainuddin; Meri Gerges; Natalia N Starkova; Lichuan Yang; Anatoly A Starkov; Flint Beal
Journal:  FASEB J       Date:  2011-08-08       Impact factor: 5.191

Review 7.  Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development.

Authors:  Adam L Boxer; Michael Gold; Edward Huey; Fen-Biao Gao; Edward A Burton; Tiffany Chow; Aimee Kao; Blair R Leavitt; Bruce Lamb; Megan Grether; David Knopman; Nigel J Cairns; Ian R Mackenzie; Laura Mitic; Erik D Roberson; Daniel Van Kammen; Marc Cantillon; Kathleen Zahs; Stephen Salloway; John Morris; Gary Tong; Howard Feldman; Howard Fillit; Susan Dickinson; Zaven Khachaturian; Margaret Sutherland; Robert Farese; Bruce L Miller; Jeffrey Cummings
Journal:  Alzheimers Dement       Date:  2012-10-05       Impact factor: 21.566

8.  Tau Accumulation, Altered Phosphorylation, and Missorting Promote Neurodegeneration in Glaucoma.

Authors:  Marius Chiasseu; Jorge L Cueva Vargas; Laurie Destroismaisons; Christine Vande Velde; Nicole Leclerc; Adriana Di Polo
Journal:  J Neurosci       Date:  2016-05-25       Impact factor: 6.167

9.  Adult-onset focal expression of mutated human tau in the hippocampus impairs spatial working memory of rats.

Authors:  Martina L Mustroph; Michael A King; Ronald L Klein; Julio J Ramirez
Journal:  Behav Brain Res       Date:  2012-04-25       Impact factor: 3.332

10.  Modeling tau pathology in human stem cell derived neurons.

Authors:  Selina Wray
Journal:  Brain Pathol       Date:  2017-07       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.